Status:
UNKNOWN
Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
Lead Sponsor:
Assiut University
Conditions:
Urinary Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients . Estimate local control, relapse free survival, overall survival and bl...
Eligibility Criteria
Inclusion
- \- Pathologically confirmation of transitional cell carcinoma . Non metastatic invasive bladder cancer (TNM0) Any age group ≥ 18 years. Non pregnant female patients.
Exclusion
- \- Other pathology than Transitional cell carcinoma Metastatic Patient Age less than 18 years
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04812145
Start Date
April 1 2021
End Date
April 1 2023
Last Update
March 23 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.